KM Financial Solutions | CORRECTED-UPDATE 2-Novartis sickle-cell drug gets U.S. FDA approval
55747
post-template-default,single,single-post,postid-55747,single-format-standard,qode-quick-links-1.0,ajax_fade,page_not_loaded,,qode_grid_1300,footer_responsive_adv,hide_top_bar_on_mobile_header,qode-child-theme-ver-1.0.0,qode-theme-ver-11.2,qode-theme-bridge,wpb-js-composer js-comp-ver-5.2.1,vc_responsive
 

CORRECTED-UPDATE 2-Novartis sickle-cell drug gets U.S. FDA approval

CORRECTED-UPDATE 2-Novartis sickle-cell drug gets U.S. FDA approval

Novartis AG on Friday won U.S.
approval for its experimental sickle cell disease drug, Adakveo,
making it the first of several proposed new therapies designed
to offer lasting relief for patients with the debilitating blood
disease to get U.S. regulatory clearance.

No Comments

Sorry, the comment form is closed at this time.